Page 119 - 2022-36-中国全科医学

·4594· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

584-585. DOI：10.1056/NEJMc1715765. study［J］. Acad Emerg Med，2020，27（1）：54-60. DOI：
［28］RAMOS C I，GONZÁLEZ-ORTIZ A，ESPINOSA-CUEVAS A， 10.1111/acem.13868.
et al. Does dietary potassium intake associate with hyperkalemia ［40］WEIR M R，BAKRIS G L，BUSHINSKY D A，et al. Patiromer
in patients with chronic kidney disease? ［J］. Nephrol Dial in patients with kidney disease and hyperkalemia receiving RAAS
Transplant，2021，36（11）：2049-2057. DOI：10.1093/ndt/ inhibitors［J］. N Engl J Med，2015，372（3）：211-221.
gfaa232. DOI：10.1056/NEJMoa1410853.
［29］ST-JULES D E，MARINARO M，GOLDFARB D S，et al. ［41］BAKRIS G L，PITT B，WEIR M R，et al. Effect of patiromer
Managing hyperkalemia：another benefit of exercise in people with on serum potassium level in patients with hyperkalemia and
chronic kidney disease? ［J］. J Ren Nutr，2020，30（5）： diabetic kidney disease：the AMETHYST-DN randomized
380-383. DOI：10.1053/j.jrn.2019.10.001. clinical trial［J］. JAMA，2015，314（2）：151-161. DOI：
［30］TRUHLÁR A，DEAKIN C D，SOAR J，et al. European 10.1001/jama.2015.7446.
Resuscitation Council Guidelines for Resuscitation 2015：section ［42］STAVROS F，YANG A，LEON A，et al. Characterization of
+
4. Cardiac arrest in special circumstances［J］. Resuscitation， structure and function of ZS-9，a K selective ion trap［J］.
2015，95：148-201. DOI：10.1016/j.resuscitation.2015.07.017. PLoS One，2014，9（12）：e114686. DOI：10.1371/journal.
［31］DAVEY M，CALDICOTT D. Calcium salts in management of pone.0114686.
hyperkalaemia［J］. Emerg Med J，2002，19（1）：92-93. ［43］LEVIEN T L，BAKER D E. Sodium Zirconium Cyclosilicate［J］.
DOI：10.1136/emj.19.1.92-a. Hospital Pharmacy，2019，54（1）：12-19.DOI：
［32］HAREL Z，KAMEL K S. Optimal dose and method of administration 10.1177/0018578718817470.
of intravenous insulin in the management of emergency ［44］KOSIBOROD M，RASMUSSEN H S，LAVIN P，et al. Effect
hyperkalemia：a systematic review［J］. PLoS One，2016，11（5）： of sodium zirconium cyclosilicate on potassium lowering for 28
e0154963. DOI：10.1371/journal.pone.0154963. days among outpatients with hyperkalemia：the HARMONIZE
［33］BATTERINK J，CESSFORD T A，TAYLOR R A. Pharmacological randomized clinical trial［J］. JAMA，2014，312（21）：2223-
interventions for the acute management of hyperkalaemia in 2233. DOI：10.1001/jama.2014.15688.
adults［J］. Cochrane Database Syst Rev，2015. DOI： ［45］PEACOCK W F，RAFIQUE Z，VISHNEVSKIY K，et al.
10.1002/14651858.cd010344. Emergency potassium normalization treatment including sodium
［34］SCHERR L，OGDEN D A，MEAD A W，et al. Management of zirconium cyclosilicate：a phase II，randomized，double-blind，
hyperkalemia with a cation-exchange resin［J］. N Engl J Med， placebo-controlled study （ENERGIZE）［J］. Acad Emerg
1961，264：115-119. DOI：10.1056/NEJM196101192640303. Med，2020，27（6）：475-486. DOI：10.1111/acem.13954.
［35］EMMETT M，HOOTKINS R E，FINE K D，et al. Effect of three ［46］SPINOWITZ B S，FISHBANE S，PERGOLA P E，et al. Sodium
laxatives and a cation exchange resin on fecal sodium and potassium zirconium cyclosilicate among individuals with hyperkalemia：
excretion［J］. Gastroenterology，1995，108（3）：752-760. a 12-month phase 3 study［J］. Clin J Am Soc Nephrol，2019，
DOI：10.1016/0016-5085(95)90448-4. 14（6）：798-809. DOI：10.2215/CJN.12651018.
［36］LAUREATI P，XU Y，TREVISAN M，et al. Initiation of sodium ［47］KASHIHARA N，YAMASAKI Y，OSONOI T，et al. A phase 3
polystyrene sulphonate and the risk of gastrointestinal adverse events multicenter open-label maintenance study to investigate the long-
in advanced chronic kidney disease：a nationwide study［J］. term safety of sodium zirconium cyclosilicate in Japanese subjects
Nephrol Dial Transplant，2020，35（9）：1518-1526. DOI： with hyperkalemia［J］. Clin Exp Nephrol，2021，25（2）：
10.1093/ndt/gfz150. 140-149. DOI：10.1007/s10157-020-01972-y.
［37］NOEL J A，BOTA S E，PETRCICH W，et al. Risk of ［48］FISHBANE S，FORD M，FUKAGAWA M，et al. A phase 3b，
hospitalization for serious adverse gastrointestinal events associated randomized，double-blind，placebo-controlled study of sodium
with sodium polystyrene sulfonate use in patients of advanced zirconium cyclosilicate for reducing the incidence of predialysis
age［J］. JAMA Intern Med，2019，179（8）：1025-1033. hyperkalemia［J］. J Am Soc Nephrol，2019，30（9）：1723-
DOI：10.1001/jamainternmed.2019.0631. 1733. DOI：10.1681/ASN.2019050450.
［38］COLBERT G B，PATEL D，LERMA E V. Patiromer ［49］KOVESDY C P，ROWAN C G，CONRAD A，et al. Real-
for the treatment of hyperkalemia［J］. Expert Rev world evaluation of patiromer for the treatment of hyperkalemia in
Clin P har m acol， 2020， 13 （ 6） ： 563 - 570. DO I： hemodialysis patients［J］. Kidney Int Rep，2019，4（2）：
10.1080/17512433.2020.1774363. 301-309. DOI：10.1016/j.ekir.2018.10.020.
［39］RAFIQUE Z，LIU M Y，STAGGERS K A，et al. Patiromer for （收稿日期：2022-03-30；修回日期：2022-05-20）
treatment of hyperkalemia in the emergency department：a pilot （本文编辑：赵跃翠）